Physician profile
Michael B Russo
NPI 1477523785
$20,311.34
in general payments reported to CMS, 2019-2025
49 companies · $3,390 in 2025
The $3,390 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $1,835 · 2021: $2,692 · 2022: $3,678 · 2023: $3,680 · 2024: $3,652 · 2025: $3,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,355 · Long Term Medical Supply Or Device Loan: $3,065 · Education: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,354.66 |
| Long Term Medical Supply Or Device Loan | $3,065.29 |
| Education | $301.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $4,086.12 | 2022-2025 | (8269) Dreamstation Cpap, Dreamstation Cpap |
| Ucb, INC. | $2,337.91 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Jazz Pharmaceuticals INC. | $2,253.66 | 2019-2025 | |
| Abbvie INC. | $1,627.75 | 2021-2025 | Ubrelvy, Qulipta |
| Neurocrine Biosciences, INC. | $1,187.25 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $828.23 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $513.11 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $490.91 | 2019-2022 | |
| Amgen INC. | $481.58 | 2019-2023 | Aimovig |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $415.57 | 2022-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $407.75 | 2023-2025 | Lumryz |
| Neurelis, INC. | $394.65 | 2020-2025 | Valtoco |
| Pfizer INC. | $387.95 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $387.55 | 2019-2022 | |
| Sk Life Science, INC. | $355.07 | 2021-2025 | Xcopri |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.